Edwards Lifesciences Corp. (EW) outperforms its competitors multiple times, despite occasional underperformance and market losses. The company consistently generates interest due to its robust Q4 and Full-Year 2023 financial results and Q3 earnings exceeding expectations. Barclays has increased EW's price target to $101.00, reflecting anticipated market strength. EW has demonstrated a year to date increase of 21.8%, amplified by EPS acceleration, which suggests its shares are poised to rally. There's also speculation about accelerating insider buying. However, some analysts question if EW's stock is overvalued, questioning investors paying above intrinsic value.
Edwards Lifesciences Corp EW News Analytics from Tue, 29 Aug 2023 07:00:00 GMT to Thu, 09 May 2024 11:43:20 GMT -
Rating 8
- Innovation 6
- Information 7
- Rumor 4
